Priority Review Granted to Novel Pneumococcal Conjugate Vaccine V114
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
The mRNA-1273 vaccine has 94.1% efficacy for preventing COVID-19 illness.
If a second dose of the first COVID-19 vaccine is not available or the maker is not known, then another vaccine may be used, new British guidelines.
Electronic cigarettes as consumer products are not associated with smoking cessation in observational studies.
The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance and prolong immune responses.
Indigenous communities in the United States have started receiving COVID-19 vaccines from federal and state agencies.
The number of Americans killed by COVID-19 topped 300,000 on December 14, the same day the country launched a massive vaccination campaign to curb the spread of COVID-19.
An Alaska health care worker is the first person in the United States reported to suffer an allergic reaction to the Pfizer COVID-19 vaccine.
High-income countries have secured supplies of COVID-19 vaccines, but access is uncertain for other countries.
As part of a 3-phase plan to combat COVID-19 outbreaks in long-term care facilities, UW Medicine has deployed drop teams to conduct rapid testing services.